Estimating nocturnal stroke onset times by magnetic resonance imaging in the WAKE-UP trial.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 19 11 2021
medline: 23 3 2022
entrez: 18 11 2021
Statut: ppublish

Résumé

Fluid-attenuated inversion recovery (FLAIR) sequences have gained a role to guide treatment of patients with unknown time of stroke symptom onset. Evolution of signal intensities in FLAIR is associated with time since stroke onset with continuous linear increases. Estimating symptom onset during night-sleep in patients from the WAKE-UP trial based on relative signal intensities FLAIR (FLAIR-rSI) from acute stroke lesions an independent dataset (PRE-FLAIR study). FLAIR-rSI was quantified in stroke lesions in PRE-FLAIR and WAKE-UP. The PRE-FLAIR study was a multicenter observational trial establishing FLAIR as a surrogate parameter for time since stroke onset. WAKE-UP was a randomized controlled trial that revealed a benefit for alteplase in patients selected based on a DWI-FLAIR mismatch. Stroke onset times were recorded in PRE-FLAIR and used to fit a linear regression model with FLAIR-rSI, adjusted for patient age and lesion volume. The model was applied to FLAIR-rSI of stroke lesions to estimate onset times in those patients enrolled in WAKE-UP who had symptom onset during night-sleep. FLAIR-rSI was quantified in 399 patients from PRE-FLAIR. Linear regression indicated a significant association of age ( Nocturnal strokes during night-sleep may predominantly occur during the early morning hours. Our results are in line with evidence of characteristic diurnal patterns of cardiovascular events.

Sections du résumé

BACKGROUND
Fluid-attenuated inversion recovery (FLAIR) sequences have gained a role to guide treatment of patients with unknown time of stroke symptom onset. Evolution of signal intensities in FLAIR is associated with time since stroke onset with continuous linear increases.
AIMS
Estimating symptom onset during night-sleep in patients from the WAKE-UP trial based on relative signal intensities FLAIR (FLAIR-rSI) from acute stroke lesions an independent dataset (PRE-FLAIR study).
METHODS
FLAIR-rSI was quantified in stroke lesions in PRE-FLAIR and WAKE-UP. The PRE-FLAIR study was a multicenter observational trial establishing FLAIR as a surrogate parameter for time since stroke onset. WAKE-UP was a randomized controlled trial that revealed a benefit for alteplase in patients selected based on a DWI-FLAIR mismatch. Stroke onset times were recorded in PRE-FLAIR and used to fit a linear regression model with FLAIR-rSI, adjusted for patient age and lesion volume. The model was applied to FLAIR-rSI of stroke lesions to estimate onset times in those patients enrolled in WAKE-UP who had symptom onset during night-sleep.
RESULTS
FLAIR-rSI was quantified in 399 patients from PRE-FLAIR. Linear regression indicated a significant association of age (
CONCLUSION
Nocturnal strokes during night-sleep may predominantly occur during the early morning hours. Our results are in line with evidence of characteristic diurnal patterns of cardiovascular events.

Identifiants

pubmed: 34791943
doi: 10.1177/17474930211059608
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-330

Subventions

Organisme : Medical Research Council
ID : MR/N003403/1
Pays : United Kingdom

Auteurs

Bastian Cheng (B)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Hans Pinnschmidt (H)

Institut für Medizinische Biometrie und Epidemiologie, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Alina Königsberg (A)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Eckhard Schlemm (E)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Florent Boutitie (F)

Hospices Civils de Lyon, Service de Biostatistique, Lyon, France.

Martin Ebinger (M)

Centrum für Schlaganfallforschung Berlin (CSB), Charité, Berlin, Germany.
Klinik für Neurologie, Medical Park Berlin Humboldtmühle, Berlin, Germany.

Matthias Endres (M)

Centrum für Schlaganfallforschung Berlin (CSB), Charité, Berlin, Germany.
Klinik und Hochschulambulanz für Neurologie, Campus Mitte, Berlin, Germany.
German Centre for Cardiovascular Research (DZHK), Berlin, Germany.
German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.

Jochen B Fiebach (JB)

Centrum für Schlaganfallforschung Berlin (CSB), Charité, Berlin, Germany.

Jens Fiehler (J)

Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ivana Galinovic (I)

Centrum für Schlaganfallforschung Berlin (CSB), Charité, Berlin, Germany.

Robin Lemmens (R)

Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Department of Neurosciences, University of Leuven, Leuven, Belgium.
Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.

Keith W Muir (KW)

Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, UK.

Salvador Pedraza (S)

Department of Radiology, Institut de Diagnostic per la Image (IDI), Girona, Spain.

Josep Puig (J)

Department of Radiology, Institut de Diagnostic per la Image (IDI), Girona, Spain.

Claus Z Simonsen (CZ)

Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.

Vincent Thijs (V)

Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia.
Austin Health, Department of Neurology, Heidelberg, Australia.

Anke Wouters (A)

Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Department of Neurosciences, University of Leuven, Leuven, Belgium.
Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.

Christian Gerloff (C)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Götz Thomalla (G)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH